Dr. Gregory's type 1 diabetes research seeks to mechanistically define the deleterious metabolic and cardiovascular effects of iatrogenic hyperinsulinemia caused by peripheral insulin delivery. He is working to translate these findings into therapeutic strategies that will restore an appropriate balance of insulin between the liver and insulin-sensitive peripheral tissues, such as hepatopreferential and oral insulin analogs and intraperitoneal insulin delivery. Ultimately, he aims to quantify the cardiovascular benefits gained when the appropriate insulin balance between hepatic and peripheral tissues is restored. Dr. Gregory's research utilizes the conscious, catheterized canine model to manipulate metabolic and hormonal conditions in vivo. He also conducts cardiometabolic research in humans in the Clinical Research Center at Vanderbilt.

>> View Publications on PubMed

Dr. Datye’s research focuses on learning about barriers to care that adolescents with type 1 diabetes face. She is also interested in developing interventions to improve adolescent self-management and ultimately glycemic control in this population. She has completed quality improvement training and uses these principles to guide her work in the endocrinology and diabetes clinics.

>> View Publications on PubMed

Dr. Russell studies ways to predict and to prevent type 1 diabetes (T1D) He is the Principal Investigator at Vanderbilt for the Type 1 Diabetes TrialNet consortium, which is funded by the National Institutes of Health to prevent type 1 diabetes in people at risk and to preserve insulin secretion in those who have T1D. He led the international abatacept trial (TN18) to determine whether an immune system modulating drug (CTLA4-Ig) can prevent the development of T1D in people at high risk to progress to full-blown T1D. He helped establish the Type 1 Diabetes Immunotherapy Clinic at the Monroe Carell Jr. Children’s Hospital at Vanderbilt to increase accessibility of newly FDA-approved therapies to patients for the delay and prevention of T1D. The Vanderbilt TrialNet Clinical Center was instrumental in demonstrating the effectiveness of the drug Tzield (teplizumab), the first of such agents FDA approved to delay progression to type 1 diabetes in individuals at risk.

>> View Publications on PubMed

Dr. Trevathan is the Multi-PI/Program Director of "Bridging the Childhood Epilepsy Treatment Gap in Africa (BRIDGE)", a large NIH-funded sixty-site cluster randomized clinical trial in three cities in northern Nigeria comparing task-shifted epilepsy care provided by community health workers versus standard care provided by physicians. He is currently conducting studies of status epilepticus among children in northern Nigeria. Dr. Trevathan also studies global health diplomacy as a tool to improve health, global security, and international relations.

Dr. Jordan's multidisciplinary clinical research program focuses on pediatric stroke, stroke prevention, sickle cell disease, and studies of brain injury and cognitive function in children with congenital heart disease and type I diabetes. In addition, Dr. Jordan and the Vanderbilt team enroll children in national and international pediatric stroke studies. The pediatric stroke program, led by Dr. Jordan, is focused on improving outcome after ischemic and hemorrhagic stroke in children. Further, she leads advanced neuroimaging studies to identify children at highest risk of stroke or subtle brain injury in children and young adults with sickle cell disease as well as co-leads clinical trials for stroke prevention in children with sickle cell disease in Nigeria.

>> View Publications on PubMed